內克塔治療在Eular 2024大會上首次展示Nktr-0165的初步臨床數據，該藥是用於

快訊 · 06/12 21:30

Nektar Therapeutics Presents First Preclinical Data on Nktr-0165, a Tnfr2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at Eular 2024

內克塔治療在Eular 2024大會上首次展示Nktr-0165的初步臨床數據，該藥是用於治療炎症性疾病的Tnfr2激動劑抗體。